Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data

Table 6

A summary of HRs for the overall and subgroup analyses of SALP and EFS of osteosarcoma patients.

	Number of studies	Patients number	HR (95% CI)	Heterogeneity
				Chi-squared		value
Overall	7	752	1.97 (1.61–2.42)	7.65	21.6%	0.265
Age
Preadult and adult	4	385	1.90 (1.45–2.48)	5.33	43.7%	0.149
Preadult only	3	367	2.07 (1.51–2.83)	2.15	7.1%	0.341
Enneking stage
II	3	321	1.88 (1.29–2.73)	1.91	0%	0.386
II-III	2	292	1.63 (1.19–2.23)	1.32	24.3%	0.250
III	2	139	2.77 (1.88–4.09)	0.01	0%	0.906
Sample size
<100	5	306	2.28 (1.68–3.09)	6.09	34.3%	0.193
>100	2	446	1.75 (1.33–2.31)	0.02	0%	0.89
Geographic region
Asia	2	112	2.34 (1.19–4.60)	1.34	25.2%	0.248
Non-Asia	5	640	1.94 (1.56–2.40)	6.05	33.8%	0.196

HR: Hazard ratio, EFS: event-free survival, and CI: confidence interval.